Video Upload Options

References

1. Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles(Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem Res.2007 Oct;32(10):1700-8.
2. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson'sdisease. Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935.
3. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L,Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G,Barbosa E, Oostra BA, Bonifati V; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.Lancet. 2005 Jan 29-Feb 4;365(9457):412-5.
4. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K,Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW.A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005 Jan29-Feb 4;365(9457):415-6.
5. Guo L, Wang W, Chen SG. Leucine-rich repeat kinase 2: relevance to Parkinson'sdisease. Int J Biochem Cell Biol. 2006;38(9):1469-75.
6. Kumar A, Cookson MR. Role of LRRK2 kinase dysfunction in Parkinson disease.Expert Rev Mol Med. 2011 Jun 13;13:e20. doi: 10.1017/S146239941100192X. Review.
7. Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, BriceA; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause ofParkinson's disease in North African Arabs. N Engl J Med. 2006 Jan26;354(4):422-3.
8. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson'sdisease: protein domains and functional insights. Trends Neurosci. 2006May;29(5):286-93.
9. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M,Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N,Bressman SB. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006 Jan 26;354(4):424-5.
10. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, BaconJA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J,Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C,Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, LinCH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS,Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V,Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK,Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; GeneticEpidemiology Of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2exonic variants with susceptibility to Parkinson's disease: a case-control study.Lancet Neurol. 2011 Oct;10(10):898-908. doi: 10.1016/S1474-4422(11)70175-2.
11. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM,Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutantLRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A. 2005 Dec20;102(51):18676-81.
12. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S,Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ.The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet. 2007 Feb;120(6):857-63.
13. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, DawsonTM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2augment kinase activity. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7.
14. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J,Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC,Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism withpleomorphic pathology. Neuron. 2004 Nov 18;44(4):601-7.